Literature DB >> 10601612

Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): results of a case-control study.

J E Nelson1, R E Harris.   

Abstract

We examined the association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs) in a case control study of 417 prostate cancer patients and 420 group-matched control subjects. Regular daily use of over the counter NSAIDs, ibuprofen or aspirin, was associated with a 66% reduction in prostate cancer risk (odds ratio = 0.34, 95% confidence interval = 0.23-0.58, p<0.01). The risk of prostate cancer was also significantly reduced in men who reported taking prescription NSAIDs (odds ratio = 0.35, 95% confidence interval = 0.15-0.84, p<0.05). These results suggest that NSAIDs may have value in the chemoprevention of prostate cancer.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10601612     DOI： 10.3892/or.7.1.169

Source DB:  PubMed          Journal:  Oncol Rep        ISSN： 1021-335X            Impact factor:   3.906


  39 in total

1.  Selective synthesis and biological evaluation of sulfate-conjugated resveratrol metabolites.

Authors:  Juma Hoshino; Eun-Jung Park; Tamara P Kondratyuk; Laura Marler; John M Pezzuto; Richard B van Breemen; Shunyan Mo; Yongchao Li; Mark Cushman
Journal:  J Med Chem       Date:  2010-07-08       Impact factor: 7.446

2.  The potential for prostate cancer chemoprevention.

Authors:  Otis W Brawley
Journal:  Rev Urol       Date:  2002

Review 3.  Cyclooxygenase-2 and thromboxane synthase in non-endocrine and endocrine tumors: a review.

Authors:  Onder Onguru; Mary B Casey; Sabine Kajita; Nobuki Nakamura; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

4.  C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): confirmatory results.

Authors:  Renee C Prins; Brooks L Rademacher; Solange Mongoue-Tchokote; Joshi J Alumkal; Julie N Graff; Kristine M Eilers; Tomasz M Beer
Journal:  Urol Oncol       Date:  2010-03-06       Impact factor: 3.498

5.  Use of aspirin and other nonsteroidal antiinflammatory medications in relation to prostate cancer risk.

Authors:  Claudia A Salinas; Erika M Kwon; Liesel M FitzGerald; Ziding Feng; Peter S Nelson; Elaine A Ostrander; Ulrike Peters; Janet L Stanford
Journal:  Am J Epidemiol       Date:  2010-08-05       Impact factor: 4.897

6.  A novel computational approach for drug repurposing using systems biology.

Authors:  Azam Peyvandipour; Nafiseh Saberian; Adib Shafi; Michele Donato; Sorin Draghici
Journal:  Bioinformatics       Date:  2018-08-15       Impact factor: 6.937

Review 7.  [Epidemiological studies for evaluating the role of cyclooxygenase in chemoprevention of malignant tumors].

Authors:  Eva S Schernhammer; Christian Dittrich
Journal:  Wien Med Wochenschr       Date:  2003

8.  Chemoprevention strategies in the prostate: an overview.

Authors:  Gary J Kelloff; Howard R Higley; Michael K Brawer; M Scott Lucia; Caroline C Sigman; E David Crawford
Journal:  Rev Urol       Date:  2002

9.  Aspirin, NSAIDs, and risk of prostate cancer: results from the REDUCE study.

Authors:  Adriana C Vidal; Lauren E Howard; Daniel M Moreira; Ramiro Castro-Santamaria; Gerald L Andriole; Stephen J Freedland
Journal:  Clin Cancer Res       Date:  2014-12-17       Impact factor: 12.531

Review 10.  Omega-3 fatty acids, genetic variants in COX-2 and prostate cancer.

Authors:  Adam C Reese; Vincent Fradet; John S Witte
Journal:  J Nutrigenet Nutrigenomics       Date:  2009-09-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.